public comments on GAMT deficiency are tentatively scheduled to provide their statements on Thursday, May 12, 2022. Members of the public registered to provide statements on all other newborn screening related topics are tentatively scheduled for Friday, May 13, 2022. Requests to provide a written statement or make oral comments to the ACHDNC must be submitted via the registration website by 12:00 p.m. ET on Friday, May 6, 2022.

Individuals who need special assistance or another reasonable accommodation should notify Alaina Harris at the address and phone number listed above at least 10 business days prior to the meeting.

#### Maria G. Button,

Director, Executive Secretariat. [FR Doc. 2022–08053 Filed 4–14–22; 8:45 am] BILLING CODE 4165–15–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Request for Comments on Scientific Questions To Be Examined To Support the Development of the Dietary Guidelines for Americans, 2025–2030

**AGENCY:** Department of Health and Human Services (HHS), Office of the Secretary, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion; Department of Agriculture (USDA), Food, Nutrition, and Consumer Services.

### ACTION: Notice.

**SUMMARY:** The Departments of Health and Human Services and Agriculture solicit written comments on the scientific questions to be examined in the review of evidence supporting the development of the *Dietary Guidelines* for Americans, 2025–2030.

**DATES:** The scientific questions are available for review and public comment. Electronic or written/paper comments will be accepted through midnight Eastern Time on May 16, 2022.

**ADDRESSES:** The scientific questions are available on the internet at *www.DietaryGuidelines.gov.* Comments and attachments submitted electronically or by paper will be posted to the *www.regulations.gov* docket. You may submit comments as follows:

• *Electronic submissions:* Follow the instructions for submitting comments at *www.regulations.gov.* 

• Written/paper submissions: Mail/ courier to Janet M. de Jesus, MS, RD, Office of Disease Prevention and Health Promotion (ODPHP) Office of the Assistant Secretary for Health (OASH), HHS; 1101 Wootton Parkway, Suite 420; Rockville, MD 20852.

SUPPLEMENTARY INFORMATION: Section 301 of the National Nutrition Monitoring and Related Research Act of 1990 (7 U.S.C. 5341) requires the Secretaries of HHS and USDA to publish the Dietary Guidelines for Americans (Dietary Guidelines) jointly at least every five years. The most recent edition of the Dietary Guidelines (2020-2025) provided guidance on the entire life span, from birth to older adulthood, including pregnancy and lactation. The Dietary Guidelines for Americans, 2025– 2030 will continue to address what to eat and drink across the entire lifespan to meet nutrient needs, promote health, and reduce the risk of chronic disease.

The Departments are identifying scientific questions to be considered in the review of evidence to support the development of the *Dietary Guidelines* for Americans, 2025–2030. Given the prevalence of chronic diseases in the United States, scientific questions will continue to examine the relationship between diet and health outcomes, and a special emphasis will be placed on questions that address food-based strategies that can be used to help individuals implement the Dietary Guidelines and prevent or manage overweight and obesity. In establishing this list of scientific questions, the Departments are considering the following criteria for prioritization: relevance to the Dietary Guidelines, importance to public health, potential impact to federal programs, avoiding duplication with other federal efforts, and research availability. The list of questions, more information on the criteria for prioritization, and background on the process for developing the questions is available at www.dietaryguidelines.gov.

• Electronic or Written Public Comments: Comments will be accepted through 11:59 p.m. Eastern Time May 16, 2022 at www.regulations.gov. Comments received by mail/courier will be considered if they are postmarked on or before May 16, 2022. Written comments via mail/courier will be uploaded into *www.regulations.gov* and are under the same limitations as for those submitted electronically to www.regulations.gov: 5,000 (with spaces) character limit for text box, and a maximum number of ten attached files and maximum size (10 MB) of each attached file. Please make note of copyright issues on your attachments. A link to the www.regulations.gov

electronic filing system will also be available at *www.DietaryGuidelines.gov.* 

HHS and USDA request comments on the list of scientific questions to be examined in the review of evidence supporting the development of the Dietary Guidelines for Americans, 2025-2030. Specifically, HHS and USDA request comments in support of or opposition to the proposed scientific questions. If a new scientific question is suggested, provide a brief summary of the topic, including information pertaining to the prioritization criteria listed above. It is requested that comments be limited to one page per topic. HHS and USDA will consider all relevant comments in finalizing the list of topics and questions to be examined in the development of the Dietary Guidelines, 2025-2030.

Contact Person for Additional Information: Janet de Jesus, MS, RD, Nutrition Advisor, telephone 240–453– 8266, Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services, DietaryGuidelines@hhs.gov.

ietary ourachines onins.

Dated: April 11, 2022.

# Rachel L. Levine,

Assistant Secretary for Health, U.S. Public Health Service. [FR Doc. 2022–08043 Filed 4–14–22; 8:45 am]

IFR Doc. 2022–08043 Filed 4–14–22; 8:45 ar BILLING CODE 4150–32–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

#### National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Human Genome Research Institute Special Emphasis Panel; Novel Synthetic NA Technology Development.

Date: May 9, 2022.

*Time:* 2:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 300, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Keith McKenney, Ph.D., National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 300 Bethesda, MD 20892, (301) 594–4280 mckenneyk@ mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: April 12, 2022.

#### Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–08109 Filed 4–14–22; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Synthesis and Distribution of Drugs of Abuse and Related Compounds.

*Date:* May 9, 2022.

*Time:* 1:00 p.m. to 2:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435–1258, marisa.srivareerat@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: April 11, 2022.

## Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–08086 Filed 4–14–22; 8:45 am] BILLING CODE 4140–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

## National Institutes of Health

## National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required).

*Date:* May 25, 2022.

*Time:* 12:00 p.m. to 2:00 p.m. *Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F52, Rockville, MD 20892 (Virtual Meeting).

*Contact Person:* Lindsey M. Pujanandez, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F52, Rockville, MD 20852, (240) 627–3206, *lindsey.pujanandez@nih.gov.* 

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 11, 2022.

#### Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–08087 Filed 4–14–22; 8:45 am] BILLING CODE 4140–01–P

### DEPARTMENT OF HOMELAND SECURITY

#### **Coast Guard**

[Docket No. USCG-2022-0159]

## National Maritime Security Advisory Committee; May 2022 Teleconference

**AGENCY:** U.S. Coast Guard, Department of Homeland Security. **ACTION:** Notice of Federal Advisory Committee teleconference meeting.

SUMMARY: The National Maritime Security Advisory Committee (Committee) will meet via teleconference, to review and discuss on matters relating to national maritime security, including on enhancing the sharing of information related to cybersecurity risks that may cause a transportation security incident, between relevant Federal agencies and (a) state, local, and tribal governments, (b) relevant public safety and emergency response agencies, (c) relevant law enforcement and security organizations, (d) maritime industry, (e) port owners and operators, and, (f) terminal owners and operators. This teleconference will be open to the public.

#### DATES:

*Meetings:* The Committee will meet by teleconference on Tuesday, May 3, 2022 from 1 p.m. until 5 p.m. Eastern Daylight Time (EDT) and on Wednesday, May 4, 2022 from 9 a.m. to noon. This teleconference may close early if all business is finished.

*Comments and supporting documentation:* To ensure your comments are received by Committee members before the teleconference, submit your written comments no later than April 22, 2022.

**ADDRESSES:** To join the teleconference or to request special accommodations, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section no later than 1 p.m. EDT on April 22, 2022, to obtain the needed information. The number of teleconference lines are limited and will be available on a firstcome, first-served basis.

Instructions: You are free to submit comments at any time, including orally at the teleconference as time permits, but if you want Committee members to review your comment before the teleconference, please submit your comments no later than April 22, 2022. We are particularly interested in comments on the issues in the "Agenda" section below. We encourage you to submit comments through Federal eRulemaking Portal at https:// regulations.gov. If your material cannot